PT Novo Nordisk Indonesia (Indonesia)

Novo Nordisk Indonesia is primarily engaged in pharmaceuticals activity. Its headquarters is located in Dki Jakarta. The company was founded in 2003. Novo Nordisk Indonesia is a subsidiary of Novo Nordisk A/S, a global healthcare company with a strong focus on diabetes care, hemophilia, growth disorders, and hormone replacement therapies. The parent company, Novo Nordisk A/S, was founded in 1923 in Denmark by August Krogh, Marie Krogh, and Hans Christian Hagedorn. In Indonesia, Novo Nordisk is dedicated to improving the lives of people with diabetes and other serious chronic conditions. The company offers a range of products, including insulin, GLP-1 receptor agonists, and other diabetes-related medications. Some of the well-known brands under Novo Nordisk include NovoRapid, Levemir, and Victoza. Novo Nordisk Indonesia operates several branches across the country, ensuring a wide geographical footprint to reach patients and healthcare providers effectively. The company is committed to expanding its presence and impact in the Indonesian market through strategic partnerships and collaborations with local healthcare organizations. Globally, Novo Nordisk operates in over 80 countries, with production facilities in Denmark, Brazil, China, and the United States. The company is a member of various international pharmaceutical and healthcare associations, actively participating in initiatives to advance medical research and patient care. Novo Nordisk Indonesia aligns with the parent company's vision of driving change to defeat diabetes and other serious chronic diseases. The company is committed to sustainability and innovation, aiming to deliver life-saving medicines and make a significant impact on global health challenges.